Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Bristol Myers Squibb Company BMY

Healthcare  —  Drug Manufacturers General
62.86 1.36 2.21% as of 25 Sep
Market cap
$125.9B
P/E
13.8×
S&P 500 Member Dividend Aristocrat
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Bristol Myers Squibb Company (BMY) EV/EBITDA

As of 25 September 2026, Bristol Myers Squibb Company (BMY) trades at a EV/EBITDA of 10.6×. Over the past ten years it has ranged from 7.0× (February 2024) to 137× (March 2025); the current reading is higher than 26% of that period. That is below the Drug Manufacturers General industry median of 13.9× and in line with the Healthcare sector median of 10.4×.

EV/EBITDA, daily

Annual

Period EV/EBITDA Change
FY2025 10.8× (91.40%)
FY2024 126× 1,573.66%
FY2023 7.5× (26.59%)
FY2022 10.2× 15.68%
FY2021 8.8× (82.26%)
FY2020 49.8× 137.96%
FY2019 20.9× 65.75%
FY2018 12.6× (26.65%)
FY2017 17.2× 8.83%
FY2016 15.8× (66.83%)

Quarterly

Period EV/EBITDA Change
Jun 2026 9.9× (16.94%)
Mar 2026 11.9× 10.55%
Dec 2025 10.8× 12.55%
Sep 2025 9.6× (3.17%)
42 more quarters

Against its own ten years

Low 7.0× High 137×
Ten-year median 15.2×
Current reading's percentile 26

EV/EBITDA against peers

Company EV/EBITDA
NVO Novo Nordisk A/S compare 7.0×
GSK GSK PLC Sponsored ADR compare 9.3×
PFE Pfizer Inc. compare 10.5×
BMY Bristol Myers Squibb Company 10.6×
SNY Sanofi compare 11.2×
AZN AstraZeneca PLC compare 13.9×
NVS Novartis AG compare 14.0×
AMGN Amgen Inc. compare 16.2×
GILD Gilead Sciences, Inc. compare 804×
Drug Manufacturers General industry median 13.9×
Healthcare sector median 10.4×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on BMY